Ticker: NTLA 🧬 
Price (Aug-22-2025, 4:00 PM ET): $10.52 (+3.90%)

🚀 Four Big Developments Since Our Last Report

1) Stock on the Move

Since our last bullish profile (April 2025), NTLA is up about 20%. In biotech world, that’s not “to the moon” yet — but it’s a healthy pulse check for a company trying to cure genetic diseases with CRISPR.

2) Insider Buy: Bill Chase Loads Up 💼💸

• Insider: William J. “Bill” Chase, Director (ex-CFO of AbbVie, 25+ years at Abbott)

• Trade Date: Aug 20, 2025

• Shares: +100,000 at $10.03 = $1M vote of confidence

• % Increase in Holdings: +288% (new total: 134,693 shares)

Chase’s résumé screams finance and pharma savvy — CFO at AbbVie post-spinout, EVP of Finance & Admin, board roles at Parexel. Translation: he knows numbers and knows drugs. His million-dollar buy feels less like “small talk” and more like “big conviction.”

3) Institutional Roll Call: Who Owns NTLA?

• ARKK (Cathie Wood’s playground): 13M shares (12.1%)

• Vanguard: 10.9M shares (10.1%)

• BlackRock: 10.0M shares (9.3%)

• Regeneron (collaborator + shareholder): 3.7M shares (3.5%)

• Baker Bros: 2.7M shares (2.5%)

Institutions own nearly 93% of float. Even ARK is still quietly adding (tiny trades last week, but buys nonetheless). When the big boys, the quants, and the biotech legends (Baker Bros) all line up — it’s worth noting.

🔍 For Intellia Therapeutics's Institutional Ownership breakdown, see here. 

4) Q2 2025 Earnings & Pipeline Update 🧪

• Cash runway: $630.5M → funds operations into 2027

• R&D expense: $97M (down from $114M)

• Net loss: -$101.3M (improvement vs -$147M YoY)

• Programs:

  • Nex-z (ATTR amyloidosis): Phase 3 MAGNITUDE trial expanding to 1,200 patients, strong early efficacy/safety

  • Lonvo-z (HAE): Phase 3 HAELO trial randomization finishing ahead of schedule; Phase 1 patients still 98% attack-free after 3 years

  • Commercial buildout: Hiring sales & ops team ahead of first anticipated launch (2027)

In CEO John Leonard’s words: “Full steam ahead.”

👉 Want the full picture? Dive into Intellia Therapeutics's financials here.

🧬 Original Report (April 2025)

👉 Cambridge, MA-based Intellia Therapeutics, Inc. is a clinical-stage gene-editing rocket ship 🚀 working to cure diseases by literally rewriting the DNA playbook with CRISPR/Cas9. Sounds sci-fi? It is. But it's also real science, backed by Nobel-winning tech, human trials, and some serious market buzz.

And last Monday (4/21/25), the market noticed: NTLA jumped nearly 10% on a brutally red day 📉 after Wolfe Research upgraded the stock to Outperform with a price target of $21—almost 3x the share price at the time. 🐺 + 📈 = 😍

⚔️ The Arsenal: Two Lead Programs, One Mission – Cure Diseases

1️⃣ Nex-Z (Formerly NTLA-2001): Taking on ATTR Amyloidosis

CRISPR-based nexiguran ziclumeran (a.k.a. nex-z) is in Phase 3 trials for ATTRv-PN—that’s short for “transthyretin amyloidosis with polyneuropathy” (we know, the name alone is a workout 🧠💪).

Basically, it's a rare, progressive, and usually fatal condition where rogue proteins from the liver go on a misfolding spree, causing chaos across nerves, hearts, and guts 😱. Intellia’s nex-z is designed to snip the problem at the genetic root, potentially offering the first-ever one-and-done cure.

🧪 The Evidence So Far?

• 90% average TTR reduction at 12 months 🧬✅

• Sustained results through 24 months across all patients in Phase 1

• No sign of waning effect (unlike your favorite New Year’s resolution)

• Generally well-tolerated (aka: no horror stories)

Regulators are already warming up: 🏛️
✔️ Orphan Drug Designation (US & EU)
✔️ RMAT Designation from the FDA
✔️ Partnered with Regeneron, so this isn’t a solo act 🎭

2️⃣ NTLA-2002: Hereditary Angioedema’s (HAE) Worst Nightmare

NTLA-2002 is another CRISPR-based, one-and-done therapy, this time for HAE, a condition where random swelling attacks make life unpredictable and terrifying. This gene editor targets the KLKB1 gene in the liver to shut down the mischief-making at the source 🧬✂️.

• Phase 3 HAELO trial kicked off in January 🌍🧪

• U.S. launch expected 2027 pending approval

• Goal? A single-dose, lifelong fix for HAE 😮🛡️

🔬 What's Cooking in the Lab?

Beyond the big two (starting late-stage clinical trials in genetic diseases), Intellia’s working on:

• Hemophilia B, again with Regeneron (where Regeneron is the lead investigator)

• Allogeneic CAR-T therapies for cancer and autoimmune chaos 🧠🔬

• NK cell therapies (your immune system’s secret agents) 🕵️♂️

• Gene delivery tech like LNPs (they're like Uber for CRISPR 🛺🧬)

Strategic partnerships in Immuno-Oncology / Autoimmune Disease include 🧑🤝🧑:

• AvenCell (universal CAR-T) 

• Kyverna (B-cell autoimmune fixers)

• ONK Therapeutics (NK cell magic)

Intellia is also collaborating with Regeneron, ReCode (genomic meds for cystic fibrosis), and others re: Research Programs for Other Targets.

🧮 The Numbers: Biotech Ain’t Cheap

• 💰 Cash: $861.7M (down from $1B a year ago) = runway through mid-2027

• 📊 Collab Revenue: $12.9M (up big from negative land, thank you Regeneron!)

• 🧪 R&D Spend: $116.9M (because curing stuff is expensive)

• 🧾 Net Loss: $128.9M in Q4 2024 (but less than last year – progress!)

Oh, and in true biotech fashion:
27% workforce reduction in 2025 and shutdown of some side projects to laser-focus on the winners.

🚦Our Funanc1al Take (Translation: We're Excited, But Not Blindfolded)

(a.k.a. We’re not saying splice it into your portfolio… but if you did, we wouldn’t snip you for it. ✂️📈)

1. 🧪 Stage 3 = Serious Biz: This ain’t a pipe dream anymore. It’s a pivotal moment.

2. 🧹 They’re trimming the fat and backing winners. That screams management with a plan 🧠

3. 📈 If it works? Wolfe’s $21 target might be way too low. We’re talking moonshot potential here 🌕🚀

4. ⚠️ But... It’s Biotech: Trials can fail. Dilution may be coming (hello, 2027). Buckle up and don’t bet the farm. 🐄💸

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

⚖️ Revised FUNanc1al Take (after update)

• Momentum: Stock rebound + insider buying + ARKK & Baker Bros holding or adding = confidence signal

• Science: Two Phase 3 shots on goal (ATTR + HAE), both showing durable efficacy

• Money: Cash runway into 2027 = no immediate dilution fears

• Risk: Still biotech. Still trials. Still binary.

But right now? Intellia looks less like a “what if” and more like a “when.”

⚠️ Disclaimer (With a Genetic Twist 🧬):

Biotech can moon… or crater. Proceed with both curiosity and caution, and maybe a CRISPR primer. 💥🔬😅🧬❤️
We laugh, we analyze, we meme. We just sell jokes and opinions — and yes, we’re billing your sense of humor. 🎪💸 
We’re not financial advisors. We’re FUNancial advisors, but we do hope to carry the mutation for spotting exciting (and risky!) biotech plays. 
Turbulence ahead? Invest at your own risk, always DYOR, hold the FOMO, and don’t invest what you can’t afford to lose.

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny